Acomhal Research has been accepted into the Johnson & Johnson Innovation – JLABS program in Washington, D.C.. This prestigious life science incubator provides state-of-the-art laboratories, equipment, and resources, along with access to a network of experts and mentors. This milestone represents a significant advancement in Acomhal Research’s mission to develop innovative therapies for cancer treatment.

“We are honored to join the JLABS community and look forward to the opportunities this collaboration will bring,” said Samy Lamouille, chief executive officer and co-founder of Acomhal Research. “The support and resources available through JLABS will be instrumental in advancing our research and achieving our mission of transforming cancer treatment.”

Acomhal Research is focused on developing cutting-edge immunotherapies and targeted treatments for various types of cancer. With a robust pipeline of promising drug candidates, the company aims to address the unmet needs of cancer patients and improve outcomes through personalized and effective treatment options.

The incubator program will provide Acomhal Research with access to a vibrant community of life science innovators, fostering collaboration and knowledge exchange. This environment will enable us to accelerate our research and development efforts, with the ultimate goal of delivering life-changing therapies to cancer patients worldwide.